WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H318805
CAS#: 67915-31-5
Description: Terconazole is an antifungal drug used to treat vaginal yeast infection. It comes as a lotion or a suppository and disrupts the biosynthesis of fats in a yeast cell. It has a relatively broad spectrum compared to azole compounds but not triazole compounds. Testing shows that it is a suitable compound for prophylaxis for those that suffer from chronic vulvovaginal candidiasis. Terconazole is a mixture of stereoisomers.
Hodoodo Cat#: H318805
Name: Terconazole
CAS#: 67915-31-5
Chemical Formula: C26H31Cl2N5O3
Exact Mass: 531.18
Molecular Weight: 532.466
Elemental Analysis: C, 58.65; H, 5.87; Cl, 13.32; N, 13.15; O, 9.01
Synonym: R42,470; R-42,470; R 42,470; R42470; R-42470; R 42470; Terconazole; (+/-)-Terconazole; Gyno-Terazol;
IUPAC/Chemical Name: Piperazine, 1-[4-[[(2R ,4S )-2-(2,4-dichlorophenyl)-2-(1H -1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-(1-methylethyl)-, rel-
InChi Key: BLSQLHNBWJLIBQ-MKNUCDGGNA-N
InChi Code: InChI=1/C26H31Cl2N5O3/c1-19(2)31-9-11-32(12-10-31)21-4-6-22(7-5-21)34-14-23-15-35-26(36-23,16-33-18-29-17-30-33)24-8-3-20(2 7)13-25(24)28/h3-8,13,17-19,23H,9-12,14-16H2,1-2H3/t23-,26-/s2
SMILES Code: C([C@]1(O[C@@H](COC2=CC=C(C=C2)N3CCN(C(C)C)CC3)CO1)C4=C(Cl)C=C(Cl)C=C4)N5C=NC=N5
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 532.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Iavazzo C, Gkegkes ID, Zarkada IM, Falagas ME. Boric acid for recurrent vulvovaginal candidiasis: the clinical evidence. J Womens Health (Larchmt). 2011 Aug;20(8):1245-55. doi: 10.1089/jwh.2010.2708. Epub 2011 Jul 20. Review. PubMed PMID: 21774671.
2: Ekiert RJ, Krzek J, Talik P. Chromatographic and electrophoretic techniques used in the analysis of triazole antifungal agents-a review. Talanta. 2010 Sep 15;82(4):1090-100. doi: 10.1016/j.talanta.2010.06.056. Epub 2010 Jul 22. Review. PubMed PMID: 20801303.
3: Young GL, Jewell D. Topical treatment for vaginal candidiasis (thrush) in pregnancy. Cochrane Database Syst Rev. 2001;(4):CD000225. Review. PubMed PMID: 11687074.
4: Ringdahl EN. Treatment of recurrent vulvovaginal candidiasis. Am Fam Physician. 2000 Jun 1;61(11):3306-12, 3317. Review. PubMed PMID: 10865926.
5: Cullins VA, Dominguez L, Guberski T, Secor RM, Wysocki SJ. Treating vaginitis. Nurse Pract. 1999 Oct;24(10):46, 49-50, 53-8 passim; quiz 64-5. Review. PubMed PMID: 10546257.
6: Sobel JD. Vulvovaginitis in healthy women. Compr Ther. 1999 Jun-Jul;25(6-7):335-46. Review. PubMed PMID: 10470518.
7: Edelman DA, Grant S. One-day therapy for vaginal candidiasis. A review. J Reprod Med. 1999 Jun;44(6):543-7. Review. PubMed PMID: 10394549.
8: Degreef H. [New antifungal agents in the treatment of superficial dermatomycoses]. Ann Dermatol Venereol. 1993;120(1):21-31. Review. French. PubMed PMID: 8393313.
9: Torres-Rodríguez JM. New topical antifungal drugs. Arch Med Res. 1993 Winter;24(4):371-5. Review. PubMed PMID: 8118161.
10: Horowitz BJ, Giaquinta D, Ito S. Evolving pathogens in vulvovaginal candidiasis: implications for patient care. J Clin Pharmacol. 1992 Mar;32(3):248-55. Review. PubMed PMID: 1564129.
11: Doering PL, Santiago TM. Drugs for treatment of vulvovaginal candidiasis: comparative efficacy of agents and regimens. DICP. 1990 Nov;24(11):1078-83. Review. PubMed PMID: 2275233.
12: Vanden Bossche H, Marichal P, Gorrens J, Coene MC. Biochemical basis for the activity and selectivity of oral antifungal drugs. Br J Clin Pract Suppl. 1990 Sep;71:41-6. Review. PubMed PMID: 2091733.
13: Weisberg M. Terconazole--a new antifungal agent for vulvovaginal candidiasis. Clin Ther. 1989 Sep-Oct;11(5):659-68. Review. PubMed PMID: 2680088.
14: Cauwenbergh G, Vanden Bossche H. Terconazole. Pharmacology of a new antimycotic agent. J Reprod Med. 1989 Aug;34(8 Suppl):588-92. Review. PubMed PMID: 2677363.
15: Fromtling RA. Overview of medically important antifungal azole derivatives. Clin Microbiol Rev. 1988 Apr;1(2):187-217. Review. PubMed PMID: 3069196; PubMed Central PMCID: PMC358042.
